See more : Medical Data Vision Co., Ltd. (3902.T) Income Statement Analysis – Financial Results
Complete financial analysis of Nuvation Bio Inc. (NUVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nuvation Bio Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- McKesson Corporation (0JZU.L) Income Statement Analysis – Financial Results
- Atlas Copco AB (ATCO-A.ST) Income Statement Analysis – Financial Results
- Public Joint Stock Company Transneft (TRNFP.ME) Income Statement Analysis – Financial Results
- China Resources Chemical Innovative Materials Co., Ltd. (301090.SZ) Income Statement Analysis – Financial Results
- Touax SCA (TOUP.PA) Income Statement Analysis – Financial Results
Nuvation Bio Inc. (NUVB)
About Nuvation Bio Inc.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 222.00K | 484.00K | 368.00K | 103.00K | 0.00 | 0.00 |
| Gross Profit | -222.00K | -484.00K | -368.00K | -103.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 71.29M | 87.82M | 69.04M | 32.60M | 25.11M | 482.67K |
| General & Administrative | 26.83M | 31.92M | 24.28M | 10.95M | 6.59M | 509.33K |
| Selling & Marketing | 1.70M | 0.00 | 0.00 | 0.00 | 400.00 | 0.00 |
| SG&A | 28.53M | 31.92M | 24.28M | 10.95M | 6.99M | 509.33K |
| Other Expenses | 0.00 | -872.00K | -644.00K | -271.00K | 0.00 | 0.00 |
| Operating Expenses | 99.82M | 119.73M | 93.32M | 43.55M | 32.18M | 992.00K |
| Cost & Expenses | 99.82M | 119.73M | 93.32M | 43.55M | 32.18M | 992.00K |
| Interest Income | 24.61M | 7.45M | 2.96M | 1.95M | 1.37K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 222.00K | 484.00K | 368.00K | 103.00K | 13.00K | 992.00K |
| EBITDA | -99.60M | -119.54M | -89.35M | -43.45M | -32.09M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -99.82M | -119.73M | -93.32M | -43.55M | -32.10M | -992.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 24.02M | 15.54M | 6.47M | 1.89M | -1.45M | 0.00 |
| Income Before Tax | -75.80M | -104.20M | -86.85M | -41.66M | -33.55M | -992.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -15.54M | -7.11M | -2.16M | 0.00 | 0.00 |
| Net Income | -75.80M | -88.66M | -79.73M | -39.50M | -33.55M | -992.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.35 | -0.41 | -0.40 | -0.40 | -0.16 | -0.01 |
| EPS Diluted | -0.35 | -0.41 | -0.40 | -0.40 | -0.16 | -0.01 |
| Weighted Avg Shares Out | 218.88M | 216.72M | 197.89M | 97.53M | 206.67M | 80.99M |
| Weighted Avg Shares Out (Dil) | 218.88M | 216.72M | 197.89M | 97.53M | 206.67M | 80.99M |
Nuvation Bio to Participate in the Jefferies Virtual Healthcare Conference
David Abrams Buys 3 Stocks in 1st Quarter
Source: https://incomestatements.info
Category: Stock Reports